Beijing Tide Pharmaceutical Becomes Biggest Shareholder Of Japanese LTT Bio-Pharma
This article was originally published in PharmAsia News
Executive Summary
According to a recent disclosure filed by LTT Bio-Pharma, a Japanese biotech startup focusing on drug delivery system discovery, Beijing Tide Pharmaceutical acquired 2,320 company shares previously owned by now-bankrupt Asklepios and became the largest shareholder with 25,320 shares. The shares account for 19.2 percent of LTT Bio-Pharma's outstanding shares. (Click here for more - Japanese language
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.